The Experts below are selected from a list of 18504 Experts worldwide ranked by ideXlab platform

Mark Adams - One of the best experts on this subject based on the ideXlab platform.

Tim Lancaster - One of the best experts on this subject based on the ideXlab platform.

  • Relapse Prevention interventions for smoking cessation
    Cochrane Database of Systematic Reviews, 2013
    Co-Authors: Peter Hajek, Lindsay F Stead, Robert West, Martin J Jarvis, Jamie Hartmannboyce, Tim Lancaster
    Abstract:

    Background: A number of treatments can help smokers make a successful quit attempt, but many initially successful quitters Relapse over time. Several interventions were proposed to help prevent Relapse. Objectives: To assess whether specific interventions for Relapse Prevention reduce the proportion of recent quitters who return to smoking. Search strategy: We searched the Cochrane Tobacco Addiction Group trials register in August 2008 for studies mentioning Relapse Prevention or maintenance in title, abstracts or keywords. Selection criteria: Randomized or quasi-randomized controlled trials of Relapse Prevention interventions with a minimum follow up of six months. We included smokers who quit on their own, or were undergoing enforced abstinence, or who were participating in treatment programmes. We included trials that compared Relapse Prevention interventions to a no intervention control, or that compared a cessation programme with additional Relapse Prevention components to a cessation programme alone. Data collection and analysis: Studies were screened and data extracted by one author and checked by a second. Disagreements were resolved by discussion or referral to a third author. Main results: Fifty-four studies met inclusion criteria, but were heterogeneous in terms of populations and interventions. We considered 36 studies that randomized abstainers separately from studies that randomized participants prior to their quit date. Looking at studies of behavioural interventions which randomised abstainers, we detected no benefit of brief and 'skills-based' Relapse Prevention methods for women who had quit smoking due to pregnancy, or for smokers undergoing a period of enforced abstinence during hospitalisation or military training. We also failed to detect significant effects of behavioural interventions in trials in unselected groups of smokers who had quit on their own or with a formal programme. Amongst trials randomising smokers prior to their quit date and evaluating the effect of additional Relapse Prevention components we also found no evidence of benefit of behavioural interventions in any subgroup. Overall, providing training in skills thought to be needed for Relapse avoidance did not reduce Relapse, but most studies did not use experimental designs best suited to the task, and had limited power to detect expected small differences between interventions. For pharmacological interventions, extended treatment with varenicline significantly reduced Relapse in one trial (risk ratio 1.18, 95% confidence interval 1.03 to 1.36). Pooling of five studies of extended treatment with bupropion failed to detect a significant effect (risk ratio 1.17; 95% confidence interval 0.99 to 1.39). Two small trials of oral nicotine replacement treatment (NRT) failed to detect an effect but treatment compliance was low and in two other trials of oral NRT randomizing short-term abstainers there was a significant effect of intervention. Authors' conclusions: At the moment there is insufficient evidence to support the use of any specific behavioural intervention for helping smokers who have successfully quit for a short time to avoid Relapse. The verdict is strongest for interventions focusing on identifying and resolving tempting situations, as most studies were concerned with these. There is little research available regarding other behavioural approaches. Extended treatment with varenicline may prevent Relapse. Extended treatment with bupropion is unlikely to have a clinically important effect. Studies of extended treatment with nicotine replacement are needed. Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

  • The Cochrane Library - Relapse Prevention interventions for smoking cessation
    Cochrane Database of Systematic Reviews, 2013
    Co-Authors: Peter Hajek, Lindsay F Stead, Robert West, Martin J Jarvis, Jamie Hartmann-boyce, Tim Lancaster
    Abstract:

    Background: A number of treatments can help smokers make a successful quit attempt, but many initially successful quitters Relapse over time. Several interventions were proposed to help prevent Relapse. Objectives: To assess whether specific interventions for Relapse Prevention reduce the proportion of recent quitters who return to smoking. Search strategy: We searched the Cochrane Tobacco Addiction Group trials register in August 2008 for studies mentioning Relapse Prevention or maintenance in title, abstracts or keywords. Selection criteria: Randomized or quasi-randomized controlled trials of Relapse Prevention interventions with a minimum follow up of six months. We included smokers who quit on their own, or were undergoing enforced abstinence, or who were participating in treatment programmes. We included trials that compared Relapse Prevention interventions to a no intervention control, or that compared a cessation programme with additional Relapse Prevention components to a cessation programme alone. Data collection and analysis: Studies were screened and data extracted by one author and checked by a second. Disagreements were resolved by discussion or referral to a third author. Main results: Fifty-four studies met inclusion criteria, but were heterogeneous in terms of populations and interventions. We considered 36 studies that randomized abstainers separately from studies that randomized participants prior to their quit date. Looking at studies of behavioural interventions which randomised abstainers, we detected no benefit of brief and 'skills-based' Relapse Prevention methods for women who had quit smoking due to pregnancy, or for smokers undergoing a period of enforced abstinence during hospitalisation or military training. We also failed to detect significant effects of behavioural interventions in trials in unselected groups of smokers who had quit on their own or with a formal programme. Amongst trials randomising smokers prior to their quit date and evaluating the effect of additional Relapse Prevention components we also found no evidence of benefit of behavioural interventions in any subgroup. Overall, providing training in skills thought to be needed for Relapse avoidance did not reduce Relapse, but most studies did not use experimental designs best suited to the task, and had limited power to detect expected small differences between interventions. For pharmacological interventions, extended treatment with varenicline significantly reduced Relapse in one trial (risk ratio 1.18, 95% confidence interval 1.03 to 1.36). Pooling of five studies of extended treatment with bupropion failed to detect a significant effect (risk ratio 1.17; 95% confidence interval 0.99 to 1.39). Two small trials of oral nicotine replacement treatment (NRT) failed to detect an effect but treatment compliance was low and in two other trials of oral NRT randomizing short-term abstainers there was a significant effect of intervention. Authors' conclusions: At the moment there is insufficient evidence to support the use of any specific behavioural intervention for helping smokers who have successfully quit for a short time to avoid Relapse. The verdict is strongest for interventions focusing on identifying and resolving tempting situations, as most studies were concerned with these. There is little research available regarding other behavioural approaches. Extended treatment with varenicline may prevent Relapse. Extended treatment with bupropion is unlikely to have a clinically important effect. Studies of extended treatment with nicotine replacement are needed. Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

  • Relapse Prevention interventions for smoking cessation.
    The Cochrane database of systematic reviews, 2009
    Co-Authors: Peter Hajek, Lindsay F Stead, Robert West, Martin Jarvis, Tim Lancaster
    Abstract:

    A number of treatments can help smokers make a successful quit attempt, but many initially successful quitters Relapse over time. Several interventions were proposed to help prevent Relapse. To assess whether specific interventions for Relapse Prevention reduce the proportion of recent quitters who return to smoking. We searched the Cochrane Tobacco Addiction Group trials register in August 2008 for studies mentioning Relapse Prevention or maintenance in title, abstracts or keywords. Randomized or quasi-randomized controlled trials of Relapse Prevention interventions with a minimum follow up of six months. We included smokers who quit on their own, or were undergoing enforced abstinence, or who were participating in treatment programmes. We included trials that compared Relapse Prevention interventions to a no intervention control, or that compared a cessation programme with additional Relapse Prevention components to a cessation programme alone. Studies were screened and data extracted by one author and checked by a second. Disagreements were resolved by discussion or referral to a third author. Fifty-four studies met inclusion criteria, but were heterogeneous in terms of populations and interventions. We considered 36 studies that randomized abstainers separately from studies that randomized participants prior to their quit date.Looking at studies of behavioural interventions which randomised abstainers, we detected no benefit of brief and 'skills-based' Relapse Prevention methods for women who had quit smoking due to pregnancy, or for smokers undergoing a period of enforced abstinence during hospitalisation or military training. We also failed to detect significant effects of behavioural interventions in trials in unselected groups of smokers who had quit on their own or with a formal programme. Amongst trials randomising smokers prior to their quit date and evaluating the effect of additional Relapse Prevention components we also found no evidence of benefit of behavioural interventions in any subgroup. Overall, providing training in skills thought to be needed for Relapse avoidance did not reduce Relapse, but most studies did not use experimental designs best suited to the task, and had limited power to detect expected small differences between interventions. For pharmacological interventions, extended treatment with varenicline significantly reduced Relapse in one trial (risk ratio 1.18, 95% confidence interval 1.03 to 1.36). Pooling of five studies of extended treatment with bupropion failed to detect a significant effect (risk ratio 1.17; 95% confidence interval 0.99 to 1.39). Two small trials of oral nicotine replacement treatment (NRT) failed to detect an effect but treatment compliance was low and in two other trials of oral NRT randomizing short-term abstainers there was a significant effect of intervention. At the moment there is insufficient evidence to support the use of any specific behavioural intervention for helping smokers who have successfully quit for a short time to avoid Relapse. The verdict is strongest for interventions focusing on identifying and resolving tempting situations, as most studies were concerned with these. There is little research available regarding other behavioural approaches. Extended treatment with varenicline may prevent Relapse. Extended treatment with bupropion is unlikely to have a clinically important effect. Studies of extended treatment with nicotine replacement are needed.

  • Relapse Prevention interventions for smoking cessation
    Cochrane Database of Systematic Reviews, 2009
    Co-Authors: Peter Hajek, Lindsay F Stead, Robert West, Martin Jarvis, Tim Lancaster
    Abstract:

    BACKGROUND: A number of treatments can help smokers make a successful quit attempt, but many initially successful quitters Relapse over time. Several interventions were proposed to help prevent Relapse. OBJECTIVES: To assess whether specific interventions for Relapse Prevention reduce the proportion of recent quitters who return to smoking. SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group trials register in August 2008 for studies mentioning Relapse Prevention or maintenance in title, abstracts or keywords. SELECTION CRITERIA: Randomized or quasi-randomized controlled trials of Relapse Prevention interventions with a minimum follow up of six months. We included smokers who quit on their own, or were undergoing enforced abstinence, or who were participating in treatment programmes. We included trials that compared Relapse Prevention interventions to a no intervention control, or that compared a cessation programme with additional Relapse Prevention components to a cessation programme alone. DATA COLLECTION AND ANALYSIS: Studies were screened and data extracted by one author and checked by a second. Disagreements were resolved by discussion or referral to a third author. MAIN RESULTS: Fifty-four studies met inclusion criteria, but were heterogeneous in terms of populations and interventions. We considered 36 studies that randomized abstainers separately from studies that randomized participants prior to their quit date.Looking at studies of behavioural interventions which randomised abstainers, we detected no benefit of brief and 'skills-based' Relapse Prevention methods for women who had quit smoking due to pregnancy, or for smokers undergoing a period of enforced abstinence during hospitalisation or military training. We also failed to detect significant effects of behavioural interventions in trials in unselected groups of smokers who had quit on their own or with a formal programme. Amongst trials randomising smokers prior to their quit date and evaluating the effect of additional Relapse Prevention components we also found no evidence of benefit of behavioural interventions in any subgroup. Overall, providing training in skills thought to be needed for Relapse avoidance did not reduce Relapse, but most studies did not use experimental designs best suited to the task, and had limited power to detect expected small differences between interventions. For pharmacological interventions, extended treatment with varenicline significantly reduced Relapse in one trial (risk ratio 1.18, 95% confidence interval 1.03 to 1.36). Pooling of five studies of extended treatment with bupropion failed to detect a significant effect (risk ratio 1.17; 95% confidence interval 0.99 to 1.39). Two small trials of oral nicotine replacement treatment (NRT) failed to detect an effect but treatment compliance was low and in two other trials of oral NRT randomizing short-term abstainers there was a significant effect of intervention. AUTHORS' CONCLUSIONS: At the moment there is insufficient evidence to support the use of any specific behavioural intervention for helping smokers who have successfully quit for a short time to avoid Relapse. The verdict is strongest for interventions focusing on identifying and resolving tempting situations, as most studies were concerned with these. There is little research available regarding other behavioural approaches. Extended treatment with varenicline may prevent Relapse. Extended treatment with bupropion is unlikely to have a clinically important effect. Studies of extended treatment with nicotine replacement are needed

Peter Hajek - One of the best experts on this subject based on the ideXlab platform.

  • Relapse Prevention interventions for smoking cessation
    Cochrane Database of Systematic Reviews, 2013
    Co-Authors: Peter Hajek, Lindsay F Stead, Robert West, Martin J Jarvis, Jamie Hartmannboyce, Tim Lancaster
    Abstract:

    Background: A number of treatments can help smokers make a successful quit attempt, but many initially successful quitters Relapse over time. Several interventions were proposed to help prevent Relapse. Objectives: To assess whether specific interventions for Relapse Prevention reduce the proportion of recent quitters who return to smoking. Search strategy: We searched the Cochrane Tobacco Addiction Group trials register in August 2008 for studies mentioning Relapse Prevention or maintenance in title, abstracts or keywords. Selection criteria: Randomized or quasi-randomized controlled trials of Relapse Prevention interventions with a minimum follow up of six months. We included smokers who quit on their own, or were undergoing enforced abstinence, or who were participating in treatment programmes. We included trials that compared Relapse Prevention interventions to a no intervention control, or that compared a cessation programme with additional Relapse Prevention components to a cessation programme alone. Data collection and analysis: Studies were screened and data extracted by one author and checked by a second. Disagreements were resolved by discussion or referral to a third author. Main results: Fifty-four studies met inclusion criteria, but were heterogeneous in terms of populations and interventions. We considered 36 studies that randomized abstainers separately from studies that randomized participants prior to their quit date. Looking at studies of behavioural interventions which randomised abstainers, we detected no benefit of brief and 'skills-based' Relapse Prevention methods for women who had quit smoking due to pregnancy, or for smokers undergoing a period of enforced abstinence during hospitalisation or military training. We also failed to detect significant effects of behavioural interventions in trials in unselected groups of smokers who had quit on their own or with a formal programme. Amongst trials randomising smokers prior to their quit date and evaluating the effect of additional Relapse Prevention components we also found no evidence of benefit of behavioural interventions in any subgroup. Overall, providing training in skills thought to be needed for Relapse avoidance did not reduce Relapse, but most studies did not use experimental designs best suited to the task, and had limited power to detect expected small differences between interventions. For pharmacological interventions, extended treatment with varenicline significantly reduced Relapse in one trial (risk ratio 1.18, 95% confidence interval 1.03 to 1.36). Pooling of five studies of extended treatment with bupropion failed to detect a significant effect (risk ratio 1.17; 95% confidence interval 0.99 to 1.39). Two small trials of oral nicotine replacement treatment (NRT) failed to detect an effect but treatment compliance was low and in two other trials of oral NRT randomizing short-term abstainers there was a significant effect of intervention. Authors' conclusions: At the moment there is insufficient evidence to support the use of any specific behavioural intervention for helping smokers who have successfully quit for a short time to avoid Relapse. The verdict is strongest for interventions focusing on identifying and resolving tempting situations, as most studies were concerned with these. There is little research available regarding other behavioural approaches. Extended treatment with varenicline may prevent Relapse. Extended treatment with bupropion is unlikely to have a clinically important effect. Studies of extended treatment with nicotine replacement are needed. Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

  • The Cochrane Library - Relapse Prevention interventions for smoking cessation
    Cochrane Database of Systematic Reviews, 2013
    Co-Authors: Peter Hajek, Lindsay F Stead, Robert West, Martin J Jarvis, Jamie Hartmann-boyce, Tim Lancaster
    Abstract:

    Background: A number of treatments can help smokers make a successful quit attempt, but many initially successful quitters Relapse over time. Several interventions were proposed to help prevent Relapse. Objectives: To assess whether specific interventions for Relapse Prevention reduce the proportion of recent quitters who return to smoking. Search strategy: We searched the Cochrane Tobacco Addiction Group trials register in August 2008 for studies mentioning Relapse Prevention or maintenance in title, abstracts or keywords. Selection criteria: Randomized or quasi-randomized controlled trials of Relapse Prevention interventions with a minimum follow up of six months. We included smokers who quit on their own, or were undergoing enforced abstinence, or who were participating in treatment programmes. We included trials that compared Relapse Prevention interventions to a no intervention control, or that compared a cessation programme with additional Relapse Prevention components to a cessation programme alone. Data collection and analysis: Studies were screened and data extracted by one author and checked by a second. Disagreements were resolved by discussion or referral to a third author. Main results: Fifty-four studies met inclusion criteria, but were heterogeneous in terms of populations and interventions. We considered 36 studies that randomized abstainers separately from studies that randomized participants prior to their quit date. Looking at studies of behavioural interventions which randomised abstainers, we detected no benefit of brief and 'skills-based' Relapse Prevention methods for women who had quit smoking due to pregnancy, or for smokers undergoing a period of enforced abstinence during hospitalisation or military training. We also failed to detect significant effects of behavioural interventions in trials in unselected groups of smokers who had quit on their own or with a formal programme. Amongst trials randomising smokers prior to their quit date and evaluating the effect of additional Relapse Prevention components we also found no evidence of benefit of behavioural interventions in any subgroup. Overall, providing training in skills thought to be needed for Relapse avoidance did not reduce Relapse, but most studies did not use experimental designs best suited to the task, and had limited power to detect expected small differences between interventions. For pharmacological interventions, extended treatment with varenicline significantly reduced Relapse in one trial (risk ratio 1.18, 95% confidence interval 1.03 to 1.36). Pooling of five studies of extended treatment with bupropion failed to detect a significant effect (risk ratio 1.17; 95% confidence interval 0.99 to 1.39). Two small trials of oral nicotine replacement treatment (NRT) failed to detect an effect but treatment compliance was low and in two other trials of oral NRT randomizing short-term abstainers there was a significant effect of intervention. Authors' conclusions: At the moment there is insufficient evidence to support the use of any specific behavioural intervention for helping smokers who have successfully quit for a short time to avoid Relapse. The verdict is strongest for interventions focusing on identifying and resolving tempting situations, as most studies were concerned with these. There is little research available regarding other behavioural approaches. Extended treatment with varenicline may prevent Relapse. Extended treatment with bupropion is unlikely to have a clinically important effect. Studies of extended treatment with nicotine replacement are needed. Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

  • Relapse Prevention interventions for smoking cessation.
    The Cochrane database of systematic reviews, 2009
    Co-Authors: Peter Hajek, Lindsay F Stead, Robert West, Martin Jarvis, Tim Lancaster
    Abstract:

    A number of treatments can help smokers make a successful quit attempt, but many initially successful quitters Relapse over time. Several interventions were proposed to help prevent Relapse. To assess whether specific interventions for Relapse Prevention reduce the proportion of recent quitters who return to smoking. We searched the Cochrane Tobacco Addiction Group trials register in August 2008 for studies mentioning Relapse Prevention or maintenance in title, abstracts or keywords. Randomized or quasi-randomized controlled trials of Relapse Prevention interventions with a minimum follow up of six months. We included smokers who quit on their own, or were undergoing enforced abstinence, or who were participating in treatment programmes. We included trials that compared Relapse Prevention interventions to a no intervention control, or that compared a cessation programme with additional Relapse Prevention components to a cessation programme alone. Studies were screened and data extracted by one author and checked by a second. Disagreements were resolved by discussion or referral to a third author. Fifty-four studies met inclusion criteria, but were heterogeneous in terms of populations and interventions. We considered 36 studies that randomized abstainers separately from studies that randomized participants prior to their quit date.Looking at studies of behavioural interventions which randomised abstainers, we detected no benefit of brief and 'skills-based' Relapse Prevention methods for women who had quit smoking due to pregnancy, or for smokers undergoing a period of enforced abstinence during hospitalisation or military training. We also failed to detect significant effects of behavioural interventions in trials in unselected groups of smokers who had quit on their own or with a formal programme. Amongst trials randomising smokers prior to their quit date and evaluating the effect of additional Relapse Prevention components we also found no evidence of benefit of behavioural interventions in any subgroup. Overall, providing training in skills thought to be needed for Relapse avoidance did not reduce Relapse, but most studies did not use experimental designs best suited to the task, and had limited power to detect expected small differences between interventions. For pharmacological interventions, extended treatment with varenicline significantly reduced Relapse in one trial (risk ratio 1.18, 95% confidence interval 1.03 to 1.36). Pooling of five studies of extended treatment with bupropion failed to detect a significant effect (risk ratio 1.17; 95% confidence interval 0.99 to 1.39). Two small trials of oral nicotine replacement treatment (NRT) failed to detect an effect but treatment compliance was low and in two other trials of oral NRT randomizing short-term abstainers there was a significant effect of intervention. At the moment there is insufficient evidence to support the use of any specific behavioural intervention for helping smokers who have successfully quit for a short time to avoid Relapse. The verdict is strongest for interventions focusing on identifying and resolving tempting situations, as most studies were concerned with these. There is little research available regarding other behavioural approaches. Extended treatment with varenicline may prevent Relapse. Extended treatment with bupropion is unlikely to have a clinically important effect. Studies of extended treatment with nicotine replacement are needed.

  • Relapse Prevention interventions for smoking cessation
    Cochrane Database of Systematic Reviews, 2009
    Co-Authors: Peter Hajek, Lindsay F Stead, Robert West, Martin Jarvis, Tim Lancaster
    Abstract:

    BACKGROUND: A number of treatments can help smokers make a successful quit attempt, but many initially successful quitters Relapse over time. Several interventions were proposed to help prevent Relapse. OBJECTIVES: To assess whether specific interventions for Relapse Prevention reduce the proportion of recent quitters who return to smoking. SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group trials register in August 2008 for studies mentioning Relapse Prevention or maintenance in title, abstracts or keywords. SELECTION CRITERIA: Randomized or quasi-randomized controlled trials of Relapse Prevention interventions with a minimum follow up of six months. We included smokers who quit on their own, or were undergoing enforced abstinence, or who were participating in treatment programmes. We included trials that compared Relapse Prevention interventions to a no intervention control, or that compared a cessation programme with additional Relapse Prevention components to a cessation programme alone. DATA COLLECTION AND ANALYSIS: Studies were screened and data extracted by one author and checked by a second. Disagreements were resolved by discussion or referral to a third author. MAIN RESULTS: Fifty-four studies met inclusion criteria, but were heterogeneous in terms of populations and interventions. We considered 36 studies that randomized abstainers separately from studies that randomized participants prior to their quit date.Looking at studies of behavioural interventions which randomised abstainers, we detected no benefit of brief and 'skills-based' Relapse Prevention methods for women who had quit smoking due to pregnancy, or for smokers undergoing a period of enforced abstinence during hospitalisation or military training. We also failed to detect significant effects of behavioural interventions in trials in unselected groups of smokers who had quit on their own or with a formal programme. Amongst trials randomising smokers prior to their quit date and evaluating the effect of additional Relapse Prevention components we also found no evidence of benefit of behavioural interventions in any subgroup. Overall, providing training in skills thought to be needed for Relapse avoidance did not reduce Relapse, but most studies did not use experimental designs best suited to the task, and had limited power to detect expected small differences between interventions. For pharmacological interventions, extended treatment with varenicline significantly reduced Relapse in one trial (risk ratio 1.18, 95% confidence interval 1.03 to 1.36). Pooling of five studies of extended treatment with bupropion failed to detect a significant effect (risk ratio 1.17; 95% confidence interval 0.99 to 1.39). Two small trials of oral nicotine replacement treatment (NRT) failed to detect an effect but treatment compliance was low and in two other trials of oral NRT randomizing short-term abstainers there was a significant effect of intervention. AUTHORS' CONCLUSIONS: At the moment there is insufficient evidence to support the use of any specific behavioural intervention for helping smokers who have successfully quit for a short time to avoid Relapse. The verdict is strongest for interventions focusing on identifying and resolving tempting situations, as most studies were concerned with these. There is little research available regarding other behavioural approaches. Extended treatment with varenicline may prevent Relapse. Extended treatment with bupropion is unlikely to have a clinically important effect. Studies of extended treatment with nicotine replacement are needed

Wei Li Fang - One of the best experts on this subject based on the ideXlab platform.

  • smoking cessation in pregnancy a review of postpartum Relapse Prevention strategies
    Journal of The American Board of Family Practice, 2004
    Co-Authors: Wei Li Fang, Adam O Goldstein, Anne Y Butzen, Allison S Hartsock, Katherine E Hartmann, Margaret Helton, Jacob A Lohr
    Abstract:

    Objective: Review and examine existing research, current strategies, and directions for future research on smoking cessation Relapse and Relapse Prevention in pregnancy and postpartum. Methods: A MEDLINE/PubMed search in 2002 and 2003 for articles containing the key words “smoking,” “pregnancy,” “cessation,” and “cessation Relapse Prevention” and references of retrieved papers yielded a review of more than 500 articles. Only 14 of these addressed program-based strategies to increase cessation among pregnant women through Relapse Prevention programs. Conclusion: Although there is much information on the rationale and strategies for smoking cessation for pregnant women, fewer studies exist on how to prevent Relapse. Maintaining and accelerating progress in cessation during pregnancy and postpartum requires more research that focuses on Relapse Prevention and cessation. Programs should incorporate stresses particular to postpartum women, should be part of routine health care, and should involve the woman’s social support network, including her partner, to maximize effectiveness.

Alan G Marlatt - One of the best experts on this subject based on the ideXlab platform.

  • Relapse Prevention maintenance strategies in the treatment of addictive behaviors 2nd ed
    2005
    Co-Authors: Alan G Marlatt, Dennis M Donovan
    Abstract:

    Marlatt, Witkiewitz, Relapse Prevention for Alcohol and Drug Problems. Blume, de la Cruz, Relapse Prevention among Diverse Populations. Kadden, Cooney, Treating Alcohol Problems. Shiffman, Kassel, Gwaltney, McChargue, Relapse Prevention for Smoking. Carroll, Rawson, Relapse Prevention for Stimulant Dependence. Haug, Sorensen, Gruber, Song, Relapse Prevention for Opioid Dependence. Roffman, Stephens, Relapse Prevention for Cannabis Abuse and Dependence. Kilmer, Cronce, Palmer, Relapse Prevention for Abuse of Club Drugs, Hallucinogens, Inhalants, and Steroids. Collins, Relapse Prevention for Eating Disorders and Obesity. Shaffer, LaPlante, Treatment of Gambling Disorders. Wheeler, George, Stoner, Enhancing the Relapse Prevention Model for Sex Offenders: Adding Recidivism Risk Reduction Therapy to Target Offenders' Dynamic Risk Needs. Zawacki, Stoner, George, Relapse Prevention for Sexually Risky Behaviors.

  • Relapse Prevention for alcohol and drug problems that was zen this is tao
    American Psychologist, 2004
    Co-Authors: Katie Witkiewitz, Alan G Marlatt
    Abstract:

    Relapse Prevention, based on the cognitive-behavioral model of Relapse, has become an adjunct to the treatment of numerous psychological problems, including (but not limited to) substance abuse, depression, sexual offending, and schizophrenia. This article provides an overview of the efficacy and effectiveness of Relapse Prevention in the treatment of addictive disorders, an update on recent empirical support for the elements of the cognitive-behavioral model of Relapse, and a review of the criticisms of Relapse Prevention. In response to the. criticisms, a reconceptualized cognitive-behavioral model of Relapse that focuses on the dynamic interactions between multiple risk factors and situational determinants is proposed. Empirical support for this reconceptualization of Relapse, the future of Relapse Prevention, and the limitations of the new model are discussed.